Somapacitan-Beco

Introduction Overview

Generic Name

somapacitan-beco

Brand Name

Sogroya

Dosage Form

injection, for subcutaneous use

Drug Class

Growth hormones

Pharmacokinetics

Absorption:
Somapacitan-beco, the active component in Sogroya, is administered subcutaneously and exhibits a prolonged absorption phase due to its molecular modification designed for extended half-life. After subcutaneous injection, absorption is gradual and sustained, leading to a relatively stable serum concentration over a week. This modified growth hormone derivative shows a bioavailability consistent with effective systemic exposure, influenced by the injection site and individual patient factors including subcutaneous tissue perfusion and local enzymatic activity.

Distribution:
Once absorbed, somapacitan-beco distributes primarily into extracellular fluids without notable extensive tissue binding. It mimics endogenous growth hormone in its binding to the growth hormone receptor distributed widely in target tissues such as liver, adipose, muscle, and bone. The volume of distribution corresponds approximately to extracellular fluid volume, indicating limited penetration into intracellular compartments. Somapacitan's molecular modifications do not significantly alter receptor affinity but allow for reduced clearance.

Metabolism:
Somapacitan is metabolized via proteolytic degradation pathways similar to endogenous human growth hormone. Proteolysis occurs predominantly in the liver and kidneys, where enzymatic cleavage breaks down the peptide into smaller inactive fragments and amino acids. Unlike endogenous growth hormone, somapacitan's albumin-binding allows decreased receptor-mediated and renal clearance, extending its metabolic stability. There is no evidence of involvement with hepatic cytochrome P450 systems, reducing potential for drug-drug interactions through metabolic pathways.

Elimination:
The elimination of somapacitan-beco is primarily through proteolytic catabolism, resulting in small peptides and amino acids subsequently reutilized or excreted. Renal excretion of intact somapacitan is minimal due to its high molecular weight and albumin-binding. The extended half-life of Sogroya enables once-weekly dosing, contrasting with the daily dosing of conventional growth hormones. The terminal half-life supports sustained pharmacodynamic effects, allowing consistent growth hormone receptor activation. Clinical studies report steady-state concentrations reached within a few weeks of weekly administration, with elimination rates supporting weekly dosing intervals.

Dosage Forms

Available Dosage Forms:
Sogroya is supplied as an autoinjector pen prefilled with somapacitan-beco for subcutaneous administration. The available strengths and formulations include:
- Autoinjector 5 mg/1.5 mL (3.3 mg/mL)
- Autoinjector 10 mg/1.5 mL (6.7 mg/mL)
- Autoinjector 15 mg/1.5 mL (10 mg/mL)

Dosages for Adults and Adolescents:
The dosing regimen for Sogroya in adults with growth hormone deficiency is typically one subcutaneous injection once weekly. The exact dose is individualized based on patient height, weight, IGF-1 levels, and clinical response, often starting at a lower dose and titrating up to achieve optimal therapeutic effect while minimizing side effects. Dose adjustments may be made every 1 to 2 weeks based on clinical evaluation and laboratory monitoring.

Specific Patient Populations:
In pediatric patients aged 2.5 years and older with growth failure due to inadequate endogenous growth hormone secretion, Sogroya is used with careful monitoring. Dose selection is weight-based and tailored to growth response and safety profile. Use in children with closed epiphyseal growth plates is contraindicated. Particular caution is warranted in children with Prader-Willi syndrome who are severely obese or have respiratory compromise; these patients are at high risk for serious adverse outcomes.

Clinical Guidelines:
Sogroya pens are designed for single patient use and should not be shared due to infection risk. Injection sites should be rotated weekly, with recommended locations including the abdomen and upper thighs. Patient education on proper injection technique and pen handling is essential for effective and safe therapy.

Mechanism Of Action

Sogroya, containing somapacitan-beco, functions as a long-acting recombinant human growth hormone analog designed to replace or supplement endogenous growth hormone in patients deficient in this hormone. It exerts its primary effect by binding to growth hormone receptors (GHR) distributed on the surface of target cells in multiple tissues, notably the liver, muscle, adipose tissue, and bone.

Upon receptor binding, somapacitan activates the JAK2-STAT signaling pathway, resulting in transcriptional activation of genes responsible for growth and metabolic regulation. A pivotal downstream effect is the induction of insulin-like growth factor-1 (IGF-1) production primarily in hepatocytes. IGF-1 mediates many systemic anabolic and growth-promoting effects attributed to growth hormone, such as the stimulation of chondrocyte proliferation and differentiation, enhancement of protein synthesis, and modulation of lipid and carbohydrate metabolism.

The molecular modification of somapacitan-beco involves attachment of a fatty acid moiety that enhances reversible binding to serum albumin. This alteration prolongs circulatory half-life by reducing receptor-mediated clearance and renal filtration. The pharmacodynamic consequence is sustained receptor activation over an extended period, enabling once-weekly dosing rather than the daily injections required for native human growth hormone.

Comparatively, somapacitan's mechanism aligns closely with other growth hormone replacement therapies, but its modifications confer distinct pharmacokinetic advantages that improve patient adherence and quality of life. Clinical trials have demonstrated comparable efficacy in improving IGF-1 levels, body composition, and metabolic parameters, supporting its mechanistic rationale and clinical utility.

Pharmacological Actions

Replacement of endogenous growth hormone in deficiency states
Stimulation of growth processes via activation of growth hormone receptors
Induction of insulin-like growth factor-1 (IGF-1) synthesis in the liver
Promotion of protein synthesis and anabolic metabolism
Enhancement of linear bone growth in children with growth hormone deficiency
Regulation of lipid metabolism including lipolysis and fat oxidation
Improvement of muscle mass and reduction of adiposity
Modulation of carbohydrate metabolism with potential effects on insulin sensitivity
Long-acting activity due to albumin binding prolongs pharmacodynamic effect
Reduction of proteolytic clearance resulting in sustained serum levels
Support of normal physiological functions altered in growth hormone deficiency
Improvement of exercise capacity and overall quality of life in deficient adults
Use in pediatric growth disorders to correct impaired somatic growth
Minimal interference with cytochrome P450 enzymes, reducing interaction risk
Subcutaneous administration allowing convenient dosing schedule

Therapeutic Or Clinical Uses

Treatment of adult growth hormone deficiency (GHD) due to hypothalamic or pituitary disease
Management of pediatric growth failure resulting from inadequate secretion of endogenous growth hormone in children aged 2.5 years and above
Replacement therapy to restore normal growth hormone activity and physiological metabolic effects
Improvement of body composition by increasing lean body mass and decreasing fat mass in GHD patients
Enhancement of bone mineral density in patients with chronic growth hormone deficiency
Reduction of cardiovascular risk factors associated with GHD such as unfavorable lipid profile
Amelioration of reduced exercise capacity and muscle strength experienced by growth hormone deficient individuals
Support for normal physical and cognitive development in children with growth hormone insufficiency
Adjunct therapy post brain irradiation in pediatric patients to restore growth hormone levels
Treatment of growth failure in children with idiopathic GHD where endogenous hormone secretion is insufficient
Used under clinical supervision for long-term management of chronic GHD in adults
Therapeutic option with improved compliance potential due to once-weekly dosing regimen
Considered when daily human growth hormone therapy is not feasible or preferred
Management of growth disorders to prevent short stature and associated complications
Enhancement of metabolic homeostasis in patients with confirmed growth hormone deficiency

Side Or Adverse Effects

Increased risk of mortality in critically ill patients with heart or stomach surgery, trauma, or severe respiratory conditions
Potential stimulation of tumor growth or recurrence in patients with known malignancies or previous brain radiation therapy
Hyperglycemia or new-onset diabetes mellitus requiring monitoring of blood glucose during treatment
Intracranial hypertension presenting with headache, visual disturbances, nausea, or vomiting
Severe allergic reactions including anaphylaxis characterized by swelling, respiratory distress, and urticaria
Fluid retention causing peripheral edema, joint and muscle pain, and symptoms of neuropathy such as burning or tingling sensations
Adrenal insufficiency manifesting as fatigue, skin darkening, dizziness, and weight loss; necessitating adrenal function evaluation
Hypothyroidism or decreased thyroid hormone levels reducing therapeutic efficacy
Pancreatitis indicated by severe, persistent abdominal pain
Injection site adverse reactions including localized fat atrophy, pain, or tissue weakness
Scoliosis progression in pediatric patients
Slipped capital femoral epiphysis in children presenting as hip/knee pain and limping
Severe adverse outcomes and sudden death risk in severely obese children with Prader-Willi syndrome and respiratory problems
Elevated serum phosphorus, alkaline phosphatase, and parathyroid hormone levels requiring biochemical monitoring
Common side effects in adults such as back pain, joint pain, dyspepsia, dizziness, tonsillitis, vomiting, hypertension, elevated creatine phosphokinase, weight gain, and anemia

Precautions

Avoid use in patients with critical illness from recent cardiac or gastrointestinal surgery, trauma, or severe respiratory failure due to increased mortality risk
Conduct thorough cancer screening prior to initiation; avoid therapy in active malignancies or tumors
Monitor blood glucose regularly due to risk of hyperglycemia or development of diabetes
Evaluate for signs of increased intracranial pressure during treatment, especially in patients with predisposing conditions
Screen for and monitor thyroid and adrenal function throughout therapy
Exercise caution in children with Prader-Willi syndrome who are severely obese or have obstructive sleep apnea due to risk of respiratory compromise
Rotate injection sites to minimize risk of lipodystrophy and localized tissue changes
Avoid use in children with closed growth plates to prevent premature epiphyseal fusion
Use with caution in patients with diabetic retinopathy or other diabetes-related ophthalmological issues
Adjust doses and monitor patients receiving concurrent glucocorticoid replacement or with adrenal insufficiency
Educate patients thoroughly in injection technique to prevent administration errors and infections
Ensure patients understand the importance of not sharing injectable devices to reduce infection transmission
Advise patients about potential allergic reactions and symptoms requiring immediate medical attention
Monitor for any behavioral or neurological changes indicating possible tumor recurrence or intracranial complications
Store medication properly to maintain stability and effectiveness; avoid freezing or exposure to extreme temperatures

Warnings

Increased mortality risk in critically ill patients with recent heart or stomach surgery, severe trauma, or respiratory failure
Potential increased risk of tumor growth or recurrence, especially in patients treated with brain or head radiation in childhood
Risk of new or worsening hyperglycemia and diabetes during therapy necessitating glucose monitoring
Possibility of intracranial hypertension with symptoms such as headache, nausea, vomiting, and vision disturbances
Serious hypersensitivity reactions including anaphylaxis requiring immediate intervention
Fluid retention risks leading to edema and peripheral neuropathy symptoms
Risk of adrenal insufficiency manifesting with fatigue and skin changes requiring hormone level assessments
Potential decrease in thyroid hormone levels affecting treatment efficiency
Risk of pancreatitis indicated by severe, persistent abdominal pain requiring urgent evaluation
Loss of subcutaneous fat and tissue weakness at injection sites warranting site rotation
Progression or worsening of scoliosis in pediatric patients
Increased risk of slipped capital femoral epiphysis in children detectable by hip or knee pain and limp
Heightened risk of sudden death in severely obese children with Prader-Willi syndrome and respiratory issues including sleep apnea
Elevations in serum phosphorus, alkaline phosphatase, and parathyroid hormone requiring biochemical monitoring
Ensure pens are used exclusively by one individual to prevent infection; never share devices

Contraindication

Active critical illness resulting from recent heart or abdominal surgery, multiple trauma, or acute respiratory failure
Presence of active malignancy or known tumor lesions
Hypersensitivity to somapacitan-beco or any ingredient in the formulation
Children with closed epiphyseal growth plates due to risk of premature growth cessation
Children with Prader-Willi syndrome who are severely obese or have significant respiratory insufficiency including sleep apnea
Patients with certain diabetic eye complications such as proliferative diabetic retinopathy
Use in patients with acute critical illness or organ failure increases mortality risk
Known hypersensitivity reactions including prior anaphylaxis to growth hormone preparations
Severe uncontrolled diabetes with frequent hyperglycemic episodes
Contraindicated if safety and efficacy cannot be assured due to comorbid conditions or contraindicated medications

Drug Interactions

Glucocorticoids may diminish the effects of somapacitan by antagonizing growth hormone action
Concurrent use of insulin or oral hypoglycemics may require dosage adjustments due to altered glucose metabolism
Agents affecting thyroid hormone levels may influence somapacitan efficacy and require monitoring and dose modifications
No significant interactions via cytochrome P450 enzymes as somapacitan is metabolized by proteolytic pathways
Potential interactions with drugs influencing fluid balance or electrolytes should be monitored due to risk of edema
Concomitant use of other growth hormone therapies is not recommended without medical supervision
Monitored use with medications altering phosphorus, alkaline phosphatase, and parathyroid hormone levels is advised
Caution with immunosuppressants or agents affecting pituitary or adrenal function
Avoid combining with medications that increase intracranial pressure to prevent additive risk
No clear evidence of interference with anticoagulants or common cardiovascular drugs
Potential for altered clearance or effect when used with drugs affecting protein binding is unlikely but monitor clinically
No known significant interactions with vaccines, though clinical judgment advised
Herbal supplements impacting endocrine or metabolic pathways should be disclosed to healthcare providers
Regular monitoring recommended when initiating or discontinuing interacting drugs to adjust somapacitan dosing accordingly
Patient education on informing healthcare providers about all medications is important to prevent interactions

Preparations Of The Drug

Sogroya is supplied as a prefilled disposable autoinjector pen for subcutaneous injection
Available in three strengths: 5 mg/1.5 mL (3.3 mg/mL), 10 mg/1.5 mL (6.7 mg/mL), and 15 mg/1.5 mL (10 mg/mL)
Each pen is intended for use by a single patient and contains specified dose quantities to allow flexible titration
Contains somapacitan-beco as the active ingredient, a long-acting growth hormone analog
Inactive ingredients include histidine, mannitol, phenol, poloxamer 188, water for injection, and pH adjusters hydrochloric acid and sodium hydroxide
The formulation is clear to slightly yellow and must be inspected visually prior to use for cloudiness or particulate matter
Storage requires refrigeration between 2°C to 8°C (36°F to 46°F) before first use; protect from freezing and extreme heat
In-use pens can be kept at room temperature not exceeding 25°C (77°F) for up to 72 hours but must then be refrigerated
Ensure pens are capped and kept in the original carton to protect from light exposure
Do not use pens beyond the expiration date printed on the packaging
The pen delivers precise dose increments selectable directly on the dose counter, improving dosing accuracy
Supplied with disposable needles that must be replaced for each injection to maintain sterility and consistent delivery
Pen systems include mechanisms to check flow prior to injection to minimize risk of dosing errors
Patient instructions emphasize proper technique, needle disposal in sharps containers, and site rotation
No modifications or refills of the pen device are permitted to ensure dosing accuracy and reduce contamination risk